Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
Times cited: 61
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
British Journal of Haematology.
Times cited: 28
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Times cited: 47